Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
h3 s3 s$ V$ h: j; L9 ]NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
3 y; X6 c* A: m3 x+ Author Affiliations; E, o% h' M$ P' J" P
: J5 d H4 }3 ~6 |2 d& \1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
( G# T4 s& C9 ?+ f2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 5 E8 n* n5 B6 Z/ s- T0 @
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
0 \; T2 f' I U% r4 _& A/ J4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
" b, [+ g: o5 ~: m5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
4 j3 O2 ~# {1 |; F9 C6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
2 H- |- t7 ~. ?7Kinki University School of Medicine, Osaka 589-8511, Japan
6 T6 b1 R2 g7 N* ^8Izumi Municipal Hospital, Osaka 594-0071, Japan 9 l" L$ ]- M! L% p( t4 [4 H7 j: F/ i
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan . N( v) a. T2 _, C
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
* [! S. X: @. p+ D* ^- p& Z$ z+ sAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
! _3 V8 ~7 v- g, l7 y! i
" c* n/ y7 T' w9 N' Y3 c4 Q4 d |